RxDoctor Payments Data

Jobin Philipose, MD

Internal Medicine · Las Cruces, NMNPI 1568818243

Payments from drug & device makers

What this record shows

Almost everything reported here is food and beverage — 97.7% of the total across 130 separate payments, which is the pattern of a clinician who attends manufacturer presentations rather than one with a consulting arrangement. 15 manufacturers reported payments, led by Johnson & Johnson at 32.1% of the total. Among internal medicine clinicians in NM with any reported payments, this total sits in the top 10% — high for the specialty, which is a reason to read the composition above rather than the number alone.

$2,481in general payments, 2019–2025

Across 130 payments — averaging $19.08 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Johnson & Johnson$795
  • AbbVie$767
  • Pfizer$307
  • Phathom Pharmaceuticals, Inc.$173
  • Takeda Pharmaceuticals U.S.A., Inc.$93
  • Ardelyx, Inc.$89
  • plus $256 from 9 others

What the payments were for

  • Food & beverage$2,42598%
  • Education$562%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$2,481 in reported general payments places this provider in the 90th percentile of 578 internal medicine providers in New Mexico.

See all internal medicine providers in New Mexico

Medicare billing

Part B allowed, 2024
$115,974
Medicare patients
427
Services billed
895

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
LinzessLinaclotide20$23,735
Budesonide DrBudesonide11$3,011
Pantoprazole Sodium105$2,215
Gavilyte-GPeg3350/Sod Sulf,bicarb,cl/Kcl105$1,550
Omeprazole46$971
Peg-3350 And ElectrolytesPeg3350/Sod Sulf,bicarb,cl/Kcl60$916
Cholestyramine LightCholestyramine12$889
Dicyclomine Hcl59$737
Famotidine39$708
Clarithromycin13$341
Peg 3350-ElectrolyteSodium Chloride/Nahco3/Kcl/Peg14$291
Lactulose11$268
Metronidazole14$174
Amoxicillin13$115
Prednisone15$34

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
AbbVieLinzess$767$23,73520 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 90th percentile of 578 internal medicine providers in New Mexico.

Other internal medicine in Las Cruces

See the full list for New Mexico

Where these figures come from

Is this you, or does something look wrong? →